Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$143.31 - $247.0 $2.48 Million - $4.27 Million
-17,303 Reduced 74.09%
6,052 $1.47 Million
Q1 2024

May 10, 2024

BUY
$146.51 - $198.2 $2.26 Million - $3.05 Million
15,394 Added 193.37%
23,355 $3.49 Million
Q4 2023

Feb 14, 2024

BUY
$151.41 - $196.57 $838,205 - $1.09 Million
5,536 Added 228.29%
7,961 $1.52 Million
Q3 2023

Nov 14, 2023

SELL
$170.77 - $211.65 $1.56 Million - $1.93 Million
-9,120 Reduced 79.0%
2,425 $429,000
Q2 2023

Aug 10, 2023

BUY
$185.01 - $212.05 $716,358 - $821,057
3,872 Added 50.46%
11,545 $2.19 Million
Q1 2023

May 15, 2023

BUY
$182.66 - $235.53 $1.4 Million - $1.81 Million
7,673 New
7,673 $1.54 Million
Q2 2022

Aug 12, 2022

BUY
$120.42 - $169.29 $816,808 - $1.15 Million
6,783 Added 169.49%
10,785 $1.57 Million
Q1 2022

May 13, 2022

SELL
$127.18 - $173.91 $2.29 Million - $3.13 Million
-17,985 Reduced 81.8%
4,002 $653,000
Q4 2021

Feb 15, 2022

BUY
$159.56 - $209.29 $888,110 - $1.16 Million
5,566 Added 33.9%
21,987 $3.73 Million
Q3 2021

Nov 15, 2021

BUY
$169.75 - $207.73 $804,615 - $984,640
4,740 Added 40.58%
16,421 $3.1 Million
Q2 2021

Aug 10, 2021

BUY
$128.63 - $176.89 $1.5 Million - $2.07 Million
11,681 New
11,681 $1.98 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $33.4B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Edgestream Partners, L.P. Portfolio

Follow Edgestream Partners, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Edgestream Partners, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Edgestream Partners, L.P. with notifications on news.